


A DEEPER DIVE INTO HEMATOLOGY AND ONCOLOGY



AN INTEGRATED ADVANTAGE

With our proven full-service outsourcing model, Medpace delivers high-quality results. In the competitive field of hematology and oncology, we have earned a reputation for taking on some of the most complex and challenging cancer research studies.


- Led by medical, operational, and regulatory experts experienced in hematology and oncology
- Integrated experts from Medpace business units including tumor imaging and central laboratory
- Deep hematology and oncology experience having managed Phase I-IV trials around the globe
- Preferred provider relationships with key sites expedites site start-up, enhances recruitment and maximizes trial efficiency
- Skilled in drug, device, and combination products

Medpace supports Sponsors who are advancing new anti-cancer therapies by providing specialized expertise in the design and management of clinical research. Our Sponsors gain a competitive edge with our integrated full-service approach in the ever-evolving landscape of drug and biologic clinical development.

EXPERT INSIGHT

Our highly experienced medical, regulatory, and operational experts work collaboratively to execute clinical trials. We understand issues from the perspective of Sponsors, clinical investigators, scientific leaders, and the reviewers at regulatory agencies. With this insight, we can successfully define and execute clear development plans for drug, device and combination products from beginning to end.

Medpace has the medical expertise, global experience, central labs, imaging labs and site relationships to complete successful studies for Sponsors.



EXPERIENCE

The Medpace hematology/oncology team has extensive clinical and research experience across a full range of solid tumor and hematologic indications and therapies from classic multi-cytotoxic agents to cutting-edge and targeted therapies. We have managed small, focused trials as well as large global studies.

Solid Tumor Including:

- Brain
- Breast
- Gastrointestinal including colorectal and non-colorectal
- Genitourinary including prostate, renal and bladder cancers
- Gynecologic
- Head and neck
- Lung
- Skin including melanoma

Malignant Hematology Including:

- Leukemia
- Lymphoma
- Myeloma

Non-Malignant Hematology

Specialty Area Include:

- Pediatric hematology/oncology
- Pediatric and adult hematopoietic stem cell transplantation
- Women's health and malignancies
- Regenerative medicine and cellular therapies
- Immunotherapies
- Gene therapies
- Precision medicine
- Adaptive study design
- Rare disease and orphan indications
- Medical device and combination products
- Diagnostics



With our unique approach to clinical research, we have earned a reputation for taking on some of the most complex and challenging cancer research studies.



SCIENTIFIC-DRIVEN DEVELOPMENT

Medpace is unique in its scientifically-driven approach to clinical research. The Medpace model gives Sponsors the advantage of early and ongoing insight and guidance from therapeutic experts throughout the trial design and execution. Our highly experienced medical doctors provide strategic direction for study design and planning, train operational staff, work with Investigators, provide medical monitoring, and meet with regulatory agencies. They are embedded throughout your studies, providing greater depth and the ability to tackle complex and challenging diseases.

ADVANCED CLINICAL PRACTITIONERS ADD A PATIENT'S PERSPECTIVE

Our medical directors are supported by a team of experienced ACPs whose unique perspective brings added value to the clinical development team. These highly-trained experts with advanced degrees and hands-on clinical experience provide an additional layer of knowledge and insights that can streamline your studies and address potential challenges early in the study planning. ACPs are embedded in the teams to ensure your study is feasible and operationalized for efficient execution by looking at the protocol through the lens of the patient and site staff. ACPs also help with the review of safety events, ongoing team education, recruitment strategies, and study document review. Their understanding of what works in a clinical setting makes them a valuable part of our embedded medical expertise model.



Lyon Gleich, MD, FACS
Senior Vice President, Medical Department



Franklin O. Smith, III, MD, FAAP, FACP
Senior Vice President, Medical Department



Blythe Thomson, MD
Senior Vice President, Medical Department



Ann Woolfrey, MD
Vice President, Medical Department



Gaston Demonty, MD
Senior Medical Director



James Fan, MD, MBBS
Senior Medical Director



Jamal Gasmî, MD, PhD
Senior Medical Director



Gregory Hale, MD, FAACP
Senior Medical Director



Kiyoshi Hashigami, MD
Senior Medical Director



Jack Bleesing, MD
Medical Director



Karine Cadren, MD
Medical Director



Jaleh Fallah, MD
Medical Director



Amanda Goldrick, MD
Medical Director



Parvin Humeau, MBChB(Hons), PhD
Medical Director



Francis LeBlanc, MD, PhD
Medical Director



Charlotte Milner-Watts, MD, MSc
Medical Director



Beata Paluchowska, MD, PhD
Medical Director



Philip Roehrs, MD
Medical Director



David Vinal Lozano, MD
Medical Director



Morihiro Watanabe, MD, PhD
Medical Director



IN-HOUSE PEDIATRICIAN BIOGRAPHIES

Lyon Gleich, MD, FACS

Senior Vice President, Medical Department

- Leading Medpace Oncology team since 2004 and experience as an oncology Investigator
- Extensive oncology clinical trial experience including immuno-oncology and new drug development, targeted therapies, biologic therapy development, multi-cytotoxic agent studies, and AE coordination
- Recognized expert in new molecular therapeutics, cancer gene therapy, and cancer immunotherapy
- Active in multiple societal memberships, including the American Society of Hematology and ASCO
- Based in Cincinnati, OH

Franklin O. Smith, III, MD, FAAP, FACP

Senior Vice President, Medical Department

- 38 years of experience in clinical, translational, and basic research
- PI on hematology, oncology, hematopoietic cell transplantation, and gene therapy clinical trials
- Senior leadership: Adult and pediatric hematology/oncology/HCT programs, cancer centers, cooperative cancer groups, FACT, FACT Consulting, Leukemia and Lymphoma Society
- Senior Vice President of the Medical Department with leadership specifically focused on Medpace's hematology studies
- 180 medical and scientific publications, book chapters and books
- Professor of Medicine and Pediatrics, University of Cincinnati
- Based in Cincinnati, OH

Blythe Thomson, MD

Senior Vice President, Medical Department

- +25 years' experience in hematology/oncology clinical trials and +9 years in biotech/CRO
- Board certified pediatric hematologist/oncologist, fellowship at UW/Fred Hutchinson Cancer Research and former Clin. Prof at Seattle Children's, Outpatient Oncology Director, Pediatric Apheresis Director and Leukemia Investigator
- Medical director including medical component of global oncology and malignant hematology programs (pediatric and adult) in biotech company and CRO

Ann Woolfrey, MD

Vice President, Medical Department

- +25 years' experience in translational & clinical research in hematologic malignancies and hematopoietic cell transplant at Fred Hutchinson Cancer Research Center (FHCRC), University of Washington, and Yale University
- Board certified in Internal Medicine & Pediatric Hematology/Oncology
- Emeritus full professor, Clinical Research Division, FHCRC/UW
- Past PI of numerous clinical trials focused on treatment of malignant & nonmalignant diseases including trials of cell and gene therapies
- >150 medical & scientific publications

Gaston Demonty, MD

Senior Medical Director

- Medical Oncologist trained in Argentina
- +20 years of clinical research experience in Europe
- +15 years of pharmaceutical industry experience at international level, both R&D and Medical Affairs
- Based in Leuven, Belgium



James Fan, MD

Senior Medical Director

- Trained in medical university hospital as a certified physician of internal medicine for 11 years
- +23 years of clinical research experience in CRO and Biotech companies in Singapore, Taiwan, and Shanghai
- Based in Shanghai

Jamal Gasmi, MD, PhD

Senior Medical Director

- Board certified medical oncologist with 27 years' experience in clinical development in oncology and hematology
- Medical Monitor for oncology Phase I/II trials with various IMP including immuno-oncology compounds and radiopharmaceuticals
- Held global medical leadership positions at numerous biopharmaceutical companies including Chief Medical Officer and Head of Regulatory Affairs
- Deputy Head and Investigator at oncology and hematology academic centers
- Active member of ASCO, ASH, AACR, and ESMO
- Based in France

Gregory Hale, MD, FAAP

Senior Medical Director

- +27 years' experience in translational and clinical research
- Academic Investigator with focus on hematologic malignancies, cell, and gene therapy
- Authored more than 210 manuscripts and chapters
- Board certified in General Pediatrics and Pediatric Hematology/Oncology
- Former Children's Oncology Group (COG) PI and national committee member
- Former PI in Therapeutic Advances in Childhood Leukemia Lymphoma (TACL)
- Leadership positions in NMDP, FACT, AAP, CIBMTR and NCI Cancer Centers
- Invited expert, NCI PDQ Pediatric AML guidance and FDA cell and gene therapy committee

Kiyoshi Hashigami, MD

Senior Medical Director

- US-trained physician with +15 years of clinical and research experience
- Prior leader in clinical development for major pharmaceutical
- Based in Tokyo, Japan

Jack Bleesing, MD

Medical Director

- Board-certified immunologist with +25 years specializing in Pediatric Cancer and Blood Diseases with additional experience in pediatric hematology/oncology with specific focus on clinical immunology, hematopoietic stem cell transplantation, gene therapy, and cellular therapies
- Former faculty member at Cincinnati Children's Hospital Medical Center, Cancer and Blood Disease Institute, in Cincinnati, OH
- +20 years of clinical and translational experience in diagnosis and treatment of inborn errors of immunity, bone marrow failure syndromes, and other rare diseases
- Served as PI/Co-PI on multiple clinical trials, including late-phase hematology studies
- CRO experience supporting Phase I-III hematology trials

Karine Cadren, MD

Medical Director

- Board certified onco-hematologist
- 6 years clinical experience – private and public practice
- Experience in pharma industry as medical science liaison/ medical advisor in hematology
- 5 years' experience in clinical research focused on oncology and hematology
- Based in Barcelona, Spain

Jaleh Fallah, MD

Medical Director

- Board-certified medical oncologist, with focus on genitourinary (GU) oncology
- Former clinical reviewer/cross-disciplinary team lead for the GU oncology at the FDA
- Expertise in regulatory strategy and clinical development for early to late stages of drug development for solid tumors



Amanda Goldrick, MD

Medical Director

- +25 years of clinical experience as medical oncology and palliative medicine physician
- +10 years research experience developing hematology-oncology products
- Phase 1-3 clinical trial experience
- Based in Sydney, Australia

Parvin Humeau, MBChB(Hons), PhD

Medical Director

- Board certified medical oncologist specializing in adult solid tumors
- +17 years clinical and research experience, +9 years oncology therapeutic and phase I-IV oncology clinical trials
- Scientific and research training: Masters in Genomic Medicine, PhD in Cancer Epigenetics, Immuno-oncology Clinical Trials Fellow (Royal Marsden Hospital)
- Extensive phase I-IV clinical trial, including first-in human and therapeutic oncology experience in multiple modalities (chemotherapy, antibody-drug conjugates, immunotherapy: checkpoint inhibitors, oncolytic viruses, bispecific antibodies, cancer vaccines and cellular therapy)
- Based in London, United Kingdom

Francis LeBlanc, MD, PhD

Medical Director

- Pediatric Hematologist/Oncologist and PhD in Molecular Medicine
- Multiple publications in peer-reviewed high-impact medical and scientific journals
- +5 years experience in clinical and translational research
- Based in Cincinnati, OH

Charlotte Milner-Watts, MD, MSc

Medical Director

- GMC registered since 2007
- +15 years clinical experience, including +9 years medical oncology clinical and research experience specializing in thoracic malignancies (Clinical Research Fellow and Specialty Doctor, Royal Marsden Hospital)
- Clinical trial experience includes patient enrolment, medical management and pharmacovigilance for patients receiving chemotherapy, immunotherapy, targeted therapy, antibody-drug conjugates, bispecific antibodies, cancer vaccines
- Masters in Oncology with Distinction, Institute of Cancer Research, University of London
- Based in London, United Kingdom

Beata Paluchowskak, MD, PhD

Medical Director

- Board certified Medical Oncologist with +15 years of experience as Medical Monitor and 10 years of clinical experience treating adults with solid tumors and hematological malignancies
- Medical Monitor experience with Phase I-III oncology trials
- Based in Warsaw, Poland

Philip Roehrs, MD

Medical Director

- +20 years of clinical and translational research in Pediatric Hematology-Oncology
- Concentrated expertise in Hematopoietic Stem Cell Transplant (HSCT) for malignant and non-malignant conditions, including inborn errors of immunity, bone marrow failure syndromes, and hemoglobinopathies
- Extensive expertise in cellular therapies, such as CAR-T, gene therapy, and viral-specific T-cells
- Academic leadership in Pediatric HSCT, Cellular Therapy, and Clinical Immunology
- Served as a Clinical Trial Investigator on reduced-intensity conditioning regimens, Cellular/Gene therapies, and HSCT toxicities
- Active member of ASH, ASBMT



David Vinal Lozano, MD


Medical Director

- Board-certified medical oncologist with +8 years of experience in clinical practice, focused in gastrointestinal tumors
- Experienced Investigator in multiple Phase I-III trials
- Previous experience in clinical research as a Medical Monitor
- Based in Madrid, Spain

Morihiro Watanabe, MD, PhD

Medical Director

- Experienced oncologist with +25 years clinical trial experience
- Prior leader of clinical development in Japan for major pharmaceutical
- Based in Tokyo, Japan




DRIVING EFFICIENT AND CONSISTENT DATA FOR GLOBAL STUDIES

Achieve quality results, meet deadlines, and maximize efficiencies by partnering with a CRO that excels in execution. Medpace demonstrates a commitment to quality and a dedication to conducting full-service studies in an exacting manner to produce the highest quality results.

KEYS TO SUCCESSFUL EXECUTION

- **Committed Teams:** With turnover rates that are lower than the industry standard, our team is with you from project initiation to completion. As a result, we typically develop better team dynamics based on trust and respect
- **Resourcefulness:** Medpace promotes a culture of problem-solving. Our global operational staff proactively identify potential issues and communicate solutions, ensuring your sites and studies are managed effectively and efficiently
- **Site and KOL relationships:** Due to Medpace's hematology and oncology experience and relationships with Investigators and opinion leaders worldwide, we can select the best sites for your specific program. This provides an advantage in meeting your recruitment timelines with high quality data. Medpace has received multiple awards recognizing Medpace as a leading global CRO, particularly noting the excellence and training of our CRAs
- **Regulatory Support:** Medpace offers a dedicated global regulatory submissions team as well as global regulatory affairs for comprehensive support



Hematology/Oncology Lab Support:


Medpace offers comprehensive and fully-integrated laboratory services including global central labs and an imaging core lab. The built-in collaboration and efficiencies of working with a single vendor facilitates a streamlined strategy for executing complex global studies.

Central Lab

- PK/PD analysis
- Biomarker development
- Flow Cytometry
- Specialty genomics and anatomical pathology

Imaging Core Lab

- Modalities
- Response Criteria including Sample Specialties



CLINTRAK® STUDY MANAGEMENT TECHNOLOGY

Medpace offers an innovative suite of proprietary, leading edge technology with ClinTrak® Clinical Suite. The ClinTrak Lab component is a full-scale Laboratory Information Management System (LIMS) that provides access to: daily lab reports, management information, cumulative results and trend graphing, secure role-based access, and study specific project management pages.

The ClinTrak Imaging component integrates image tracking, quantitative and qualitative analysis, and data management to store and manage data from all imaging and reading centers. Integrated clinical trial services deliver efficient and streamlined execution.

FULL-SERVICE CLINICAL DEVELOPMENT

Medpace is a scientifically-driven, global, full-service clinical contract research organization providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace's mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective.

**WE CAN'T SIMPLIFY
CLINICAL DEVELOPMENT –
BUT WE CAN EXECUTE
IT SEAMLESSLY.**

